JP2005519059A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519059A5
JP2005519059A5 JP2003557592A JP2003557592A JP2005519059A5 JP 2005519059 A5 JP2005519059 A5 JP 2005519059A5 JP 2003557592 A JP2003557592 A JP 2003557592A JP 2003557592 A JP2003557592 A JP 2003557592A JP 2005519059 A5 JP2005519059 A5 JP 2005519059A5
Authority
JP
Japan
Prior art keywords
gly
ala
glu
arg
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003557592A
Other languages
English (en)
Japanese (ja)
Other versions
JP4733922B2 (ja
JP2005519059A (ja
Filing date
Publication date
Priority claimed from GBGB0200507.2A external-priority patent/GB0200507D0/en
Priority claimed from PCT/US2002/031944 external-priority patent/WO2003026591A2/en
Application filed filed Critical
Priority claimed from PCT/GB2003/000062 external-priority patent/WO2003057235A2/en
Publication of JP2005519059A publication Critical patent/JP2005519059A/ja
Publication of JP2005519059A5 publication Critical patent/JP2005519059A5/ja
Application granted granted Critical
Publication of JP4733922B2 publication Critical patent/JP4733922B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003557592A 2002-01-10 2003-01-10 摂食行動の修正 Expired - Fee Related JP4733922B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0200507.2 2002-01-10
GBGB0200507.2A GB0200507D0 (en) 2002-01-10 2002-01-10 Appetite suppression
US39210902P 2002-06-28 2002-06-28
US60/392,109 2002-06-28
PCT/US2002/031944 WO2003026591A2 (en) 2001-09-24 2002-09-24 Modification of feeding behavior
USPCT/US02/31944 2002-09-24
PCT/GB2003/000062 WO2003057235A2 (en) 2002-01-10 2003-01-10 Modification of feeding behavior

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009193064A Division JP5226628B2 (ja) 2002-01-10 2009-08-24 摂食行動の修正
JP2010275256A Division JP2011052018A (ja) 2002-01-10 2010-12-10 摂食行動の修正

Publications (3)

Publication Number Publication Date
JP2005519059A JP2005519059A (ja) 2005-06-30
JP2005519059A5 true JP2005519059A5 (enExample) 2006-03-02
JP4733922B2 JP4733922B2 (ja) 2011-07-27

Family

ID=32992571

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003557592A Expired - Fee Related JP4733922B2 (ja) 2002-01-10 2003-01-10 摂食行動の修正
JP2009193064A Expired - Fee Related JP5226628B2 (ja) 2002-01-10 2009-08-24 摂食行動の修正
JP2010275256A Pending JP2011052018A (ja) 2002-01-10 2010-12-10 摂食行動の修正

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009193064A Expired - Fee Related JP5226628B2 (ja) 2002-01-10 2009-08-24 摂食行動の修正
JP2010275256A Pending JP2011052018A (ja) 2002-01-10 2010-12-10 摂食行動の修正

Country Status (5)

Country Link
EP (2) EP2329839B1 (enExample)
JP (3) JP4733922B2 (enExample)
AU (2) AU2003201998C1 (enExample)
CA (1) CA2472882A1 (enExample)
WO (1) WO2003057235A2 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
CA2431800C (en) 2000-12-14 2014-07-08 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
BR0212985A (pt) 2001-09-24 2005-08-30 Imp College Innovations Ltd Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2510199A1 (en) 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2004089279A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Long-acting derivatives of pyy agonists
US20090105122A1 (en) * 2003-11-25 2009-04-23 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
EP1694356B1 (en) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
BRPI0507594A (pt) 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc polipetìdeos hìbridos com propriedades selecionáveis
US8193310B2 (en) 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
JP2007530028A (ja) * 2004-03-24 2007-11-01 アンテグラジャン ペプチドホルモンをコードするヒト肥満感受性遺伝子及びその使用
WO2005110457A2 (en) * 2004-05-18 2005-11-24 Aditech Pharma Ab Treatment of eating disorders and induction of lipolysis
JP2008501765A (ja) * 2004-06-11 2008-01-24 ノボ ノルディスク アクティーゼルスカブ Glp−1アゴニストを用いた薬剤誘発性肥満の中和
AU2005295043A1 (en) 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ES2325773T5 (es) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
EP3000826A1 (en) * 2004-12-13 2016-03-30 Amylin Pharmaceuticals, LLC Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
SI1845942T1 (sl) 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
KR101245022B1 (ko) 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1853627A2 (en) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
GB0504857D0 (en) * 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
DK1888031T3 (da) * 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
EP1954313A1 (en) * 2005-11-01 2008-08-13 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012507558A (ja) * 2008-11-05 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション ニューロメジンuの作用メカニズムおよびその用途
WO2010096052A1 (en) * 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US20120058116A1 (en) * 2009-04-24 2012-03-08 Andrew Beaton Fgfr1c antibody combinations
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
SG184860A1 (en) 2010-04-27 2012-11-29 Agency Science Tech & Res Eif4e binding peptides
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012054523A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US20130172244A1 (en) * 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2834318T3 (es) 2012-05-25 2021-06-17 Camurus Ab Formulaciones de agonistas de receptores de la somatostatina
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
EP3625247A4 (en) * 2017-05-16 2021-03-24 The University of Chicago COMPOSITIONS AND METHODS FOR TREATMENT AND / OR PREVENTION OF PATHOGENIC FUNGAL INFECTIONS AND MAINTAINING MICROBIOMAL COMENSALISM
KR20200132852A (ko) * 2018-01-23 2020-11-25 길라 테라퓨틱스, 인코포레이티드 펩티드 yy 약학적 제형, 조성물, 및 방법
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CN118496217A (zh) 2018-11-20 2024-08-16 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
EP4366755A4 (en) * 2021-07-08 2025-09-24 Gila Therapeutics Inc COMPOSITIONS AND METHODS FOR ACTIVATING A NEURAL RECEPTOR

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE159858T1 (de) 1983-09-26 1997-11-15 Ehrenfeld Udo Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
FI906411A7 (fi) 1988-06-28 1990-12-27 La Jolla Cancer Res Foundation Solujen lisääntymisen esto Decorinilla
US5026685A (en) 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE9002278L (sv) 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
ATE180510T1 (de) 1991-11-06 1999-06-15 Garvan Inst Med Res Humaner neuropeptid y-y1 rezeptor
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
EP0692971A4 (en) 1993-03-29 1997-11-12 Univ Cincinnati PEPTID YY ANALOGS AND USES THEREFOR
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
PL189137B1 (pl) 1996-02-02 2005-06-30 Alza Corp Implantowane urządzenie do dostarczania substancji aktywnej
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP4798814B2 (ja) * 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ,インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6306819B1 (en) * 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
EP0920864A1 (en) * 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ N末端修飾glp−1誘導体
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
US7396809B1 (en) * 1999-02-10 2008-07-08 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
EP1165519A1 (en) 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
ATE372782T1 (de) 1999-06-21 2007-09-15 Lilly Co Eli Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
CA2382528A1 (en) 1999-08-25 2001-03-01 Banyu Pharmaceutical Co., Ltd. Novel isoindole derivatives
AU6798000A (en) 1999-08-26 2001-03-19 Viropharma Incorporated Compounds, compositions and methods for treating influenza
EP1239871A1 (en) 1999-11-12 2002-09-18 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
JP2003519667A (ja) * 2000-01-10 2003-06-24 アミリン・ファーマシューティカルズ,インコーポレイテッド トリグリセリドレベルの調節および脂質異常血症の治療のためのエキセンジンおよびそのアゴニストの使用
WO2001066135A1 (en) 2000-03-08 2001-09-13 Novo Nordisk A/S Lowering serum lipids
WO2001089554A2 (en) 2000-05-19 2001-11-29 Bionebraska, Inc. Treatment of acute coronary syndrome with glp-1
PL365779A1 (en) 2000-07-06 2005-01-10 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
CA2431800C (en) * 2000-12-14 2014-07-08 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders
WO2002066479A1 (en) 2001-02-23 2002-08-29 Banyu Pharmaceutical Co.,Ltd. Novel isoindole derivatives
WO2002067918A1 (en) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Novel diallylmethylamine derivative

Similar Documents

Publication Publication Date Title
JP2005519059A5 (enExample)
JP2004501162A5 (enExample)
DK1531791T3 (da) Forebyggelse og begrænsning af iskæmi
JP2005505579A5 (enExample)
WO2006029393A8 (en) Process for preparation of mixtures of polypeptides using purified hydrobromic acid
JP2010529957A5 (enExample)
DE60313858D1 (de) Peptidhaltige kosmetische oder pharmazeutische zusammensetzung
JP2004521123A5 (enExample)
CO5640143A2 (es) Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico
JP2005516996A5 (enExample)
WO2004009615A3 (en) Cd40-ligand lacking native-pattern glycosylation
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
WO2003075944A3 (en) Interferon beta-like molecules for treatment of stroke
ATE291033T1 (de) Therapeutische peptide
WO2001042287A3 (en) Putative human g-protein coupled receptors
JP2006510360A5 (enExample)
WO1998025955A3 (en) Cloned glucagon-like peptide-2 receptors
DE60036676D1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
WO2002036633A3 (en) Human 7tm proteins and polynucleotides encoding the same
WO2002088183A3 (en) G-protein coupled receptor
WO2003033536A3 (en) G-protein coupled receptor
WO2001081411A3 (en) Human 7-transmembrane g-protein coupled receptors and polynucleotides encoding the same
WO2001072842A3 (en) Human 7-transmembrane proteins and polynucleotides encoding the same
WO2002092624A3 (en) G-protein coupled receptor
EP1225183A3 (en) Human G-protein coupled receptor